1.52 -0.3 (-16.48%) | 04-18 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 2.83 | 1-year : | 4.08 |
Resists | First : | 2.43 | Second : | 3.5 |
Pivot price | 0.98 | |||
Supports | First : | 0.69 | Second : | 0.58 |
MAs | MA(5) : | 1.13 | MA(20) : | 1.01 |
MA(100) : | 1.15 | MA(250) : | 2.31 | |
MACD | MACD : | 0 | Signal : | -0.1 |
%K %D | K(14,3) : | 27.2 | D(3) : | 19.4 |
RSI | RSI(14): 63.4 | |||
52-week | High : | 10.5 | Low : | 0.5 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ INVO ] has closed below upper band by 3.9%. Bollinger Bands are 126.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
If tomorrow: | Open lower | Open higher |
High: | 1.71 - 1.72 | 1.72 - 1.73 |
Low: | 1.31 - 1.32 | 1.32 - 1.33 |
Close: | 1.5 - 1.52 | 1.52 - 1.53 |
INVO Bioscience, Inc., a commercial-stage fertility company, provides assisted reproductive technology solutions worldwide. Its flagship product is the INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. The company was founded in 2007 and is based in Sarasota, Florida.
Wed, 17 Apr 2024
Healthcare Stocks in Play - INVO Bioscience (Nasdaq: INVO) Soars on Fourth Quarter and Full Year 2023 Financial ... - Investorideas.com newswire
Wed, 17 Apr 2024
Why Invo BioScience Stock Is Soaring Today - INVO Bioscience (NASDAQ:INVO) - Benzinga
Wed, 17 Apr 2024
BestGrowthStocks.Com Issues Comprehensive Analysis Regarding INVO Biosciences Merger - The Globe and Mail
Wed, 17 Apr 2024
Why Is Invo Bioscience (INVO) Stock Up 85% Today? - MSN
Wed, 17 Apr 2024
Why Is Invo Bioscience (INVO) Stock Up 85% Today? - InvestorPlace
Wed, 17 Apr 2024
Why INVO Bioscience Shares Are Trading Higher By Around 73%; Here Are 20 Stocks Moving Premarket - Markets Insider
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Medical - Devices
|
|
Shares Out | 0 (M) |
Shares Float | 3 (M) |
Held by Insiders | 2.45e+006 (%) |
Held by Institutions | 0.8 (%) |
Shares Short | 11 (K) |
Shares Short P.Month | 0 (K) |
EPS | -7.9e+006 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | -91 % |
Return on Assets (ttm) | -41.3 % |
Return on Equity (ttm) | -1 % |
Qtrly Rev. Growth | 1.92e+006 % |
Gross Profit (p.s.) | 210.93 |
Sales Per Share | 40.97 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | -10.4 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | -5 (M) |
PE Ratio | -0.01 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | 0.03 |
Price to Cash Flow | 15.09 |
Dividend | 0 |
Forward Dividend | 12060 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |